Sonoma Pharmaceuticals & MicroSafe Group Announce That Microsafe® Disinfectant & Sanitizer Manufactured Using Sonoma’s Mic...
28 Juli 2020 - 10:05PM
Business Wire
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare
leader developing and producing stabilized hypochlorous acid (HOCl)
products for a wide range of applications, including wound care,
eye care and dermatological conditions and the MicroSafe Group
Dubai announce that Microsafe® Disinfectant & Sanitizer
manufactured by Sonoma successfully passed both the Boeing
Specification Standard BSS7434 and the British Aerospace Airbus
specification AIMS09-00-002. The passing of these tests validate
the compatibility and safety of the Microsafe® Disinfectant &
Sanitizer on the interior and exterior parts and materials of
Boeing and Airbus commercial transport aircraft.
“Conforming with the material compatibility standards set forth
by Boeing & Airbus, together with our 30 second kill time of
bacteria & viruses on hard surfaces, allows us to advance the
use of Microsafe® Disinfectant & Sanitizer into the airline
industry. Recently, Microsafe® Disinfectant & Sanitizer (brand
name “Nanocyn” in Australia) was approved and entered into the
Australian Register of Therapeutic Goods (ARTG) for use against
SARS-CoV-2 (COVID-19) with a 30 second kill time,” said Mrs. Safa
Qadumi, Founder and CEO of the MicroSafe Group Dubai.
“It’s important to note, that the Microsafe® Disinfectant &
Sanitizer has been successfully used for nearly 20 years globally
to fight the spread of infectious disease and during this time, we
have earned numerous global regulatory approvals and amassed
reputable scientific evidence not only as a surface disinfectant,
but as a skin and wound antiseptic as well,” Mrs. Safa,
continued.
“We are excited that these tests show that use of our Microcyn®
technology conforms to aircraft manufacturer standards. These test
results expand our potential sales channels into the airline
industry,” said Amy Trombly, CEO of Sonoma Pharmaceuticals. She
continued, “As disinfectant and sanitizer use has increased due to
the pandemic that has spread around the world, we are excited to
work with our partners, like MicroSafe Group, to make a positive
difference by providing safer environments for people during this
difficult time. As an international company selling products in 53
countries around the world, we are continuously seeking additional
partners to expand our domestic and global reach in distributing
our products.”
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for
developing and producing stabilized hypochlorous acid (HOCl)
products for a wide range of applications, including wound care,
animal health care, eye care, nasal care, oral care and
dermatological conditions. The company’s products reduce
infections, itch, pain, scarring and harmful inflammatory responses
in a safe and effective manner. In-vitro and clinical studies of
hypochlorous acid (HOCl) show it to have impressive antipruritic,
antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s
stabilized HOCl immediately relieves itch and pain, kills pathogens
and breaks down biofilm, does not sting or irritate skin and
oxygenates the cells in the area treated assisting the body in its
natural healing process. The company’s products are sold either
directly or via partners in 53 countries worldwide and the company
actively seeks new distribution partners. The company’s principal
office is in Woodstock, Georgia, with manufacturing operations in
Latin America. European marketing and sales are headquartered in
Roermond, Netherlands. More information can be found at
www.sonomapharma.com. For partnership opportunities, please contact
businessdevelopment@sonomapharma.com.
About MicroSafe Group
The MicroSafe Group is multi-nation company with its head office
in Dubai, United Arab Emirates. With several regional offices in
the Middle East, as well as MicroSafe Care Australia, MicroSafe
Group is able to provide innovative solutions to a wide range of
industries and healthcare providers. The MicroSafe Group promotes
only those products it believes will truly revolutionize healthcare
– products that will enrich the lives of patients and healthcare
professionals all over the world. Interested distributors may
contact the MicroSafe Group at info@microsafecare.com or contact
Mr. Safwan Abdallah, Director of International Business Development
at safwan@microsafecare.com. More information can be found at
www.microsafe.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release are forward-looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial and
technology progress and future financial performance of Sonoma
Pharmaceuticals, Inc. and its subsidiaries (the “company”). These
forward-looking statements are identified by the use of words such
as “continue,” “advance,” “develop” and “expand,” among others.
Forward-looking statements in this press release are subject to
certain risks and uncertainties inherent in the company’s business
that could cause actual results to vary, including such risks that
regulatory clinical and guideline developments may change,
scientific data may not be sufficient to meet regulatory standards
or receipt of required regulatory clearances or approvals, clinical
results may not be replicated in actual patient settings,
protection offered by the company’s patents and patent applications
may be challenged, invalidated or circumvented by its competitors,
the available market for the company’s products will not be as
large as expected, the company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to meet the company’s cash needs, fund further
development, as well as uncertainties relative to the COVID-19
pandemic and economic development, varying product formulations and
a multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the company’s filings with the Securities and
Exchange Commission. The company disclaims any obligation to update
these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™, Microcyn® and Microdacyn60® are
trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc.
All other trademarks and service marks are the property of their
respective owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200728005842/en/
Media and Investor Contact: Sonoma Pharmaceuticals,
Inc. ir@sonomapharmaceuticals.com
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024